NCT06276764
The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)
Enrolling by Invitation
Not specifiedAges 18–90ObservationalAdenocyte, LLC
~500 participants
Updated 2025-03-07 on ClinicalTrials.gov
What's tested:LINFU®
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The number of pancreatic ductal adenocarcinomas or their precursor lesions, dysplasia, identified only with LINFU® will be compared to standard screening methods
Measured over 5 years
Conditions
Where it's being run
1 sites across 1 statesNew York1
Study leadership
- Gregory Haber, MD FRCP · PRINCIPAL_INVESTIGATOR · Manhattan Endoscopy Center
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- The number of pancreatic ductal adenocarcinomas or their precursor lesions, dysplasia, identified only with LINFU® will be compared to standard screening methods5 years
The total number of asymptomatic pancreatic ductal adenocarcinomas and their noninvasive precursor lesions identified with LINFU® by analysis of pancreatic fluid will be compared to the number of these lesions identified with current screening tests, including EUS, CH-EUS, CEUS, MRI/MRCP, PET/CT, CT